PaclitaxelAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsCarboplatinDrug Administration ScheduleOvarian NeoplasmsInfusions, IntravenousTubulin ModulatorsCisplatinTreatment OutcomeDrug Resistance, NeoplasmAntineoplastic AgentsLung NeoplasmsTaxoidsBreast NeoplasmsDoxorubicinBridged CompoundsArea Under CurveNeutropeniaCarcinoma, Non-Small-Cell LungDose-Response Relationship, DrugCell Line, TumorDrug SynergismTaxusDeoxycytidineEpothilonesTubulinPharmaceutical VehiclesDisease-Free SurvivalAdministration, OralNeoplasmsP-GlycoproteinSurvival AnalysisMaximum Tolerated DoseCombined Modality TherapyMice, NudeTime FactorsEpirubicinPeripheral Nervous System DiseasesTopotecanVinblastineFallopian Tube NeoplasmsMicrotubulesTumor Cells, CulturedApoptosisSurvival RateDrug CarriersXenograft Model Antitumor AssaysDrug Delivery SystemsNeoplasm StagingCyclophosphamideDrug Resistance, MultipleAntibodies, Monoclonal, HumanizedRadiation DosageDrug InteractionsDrug Screening Assays, AntitumorLeukopeniaLethal Dose 50FluorouracilIfosfamideDose FractionationThrombocytopeniaPeritoneal NeoplasmsNanoparticlesGranulocyte Colony-Stimulating FactorHematologic DiseasesCell SurvivalFeasibility StudiesRadiotherapy DosageNeoplasms, Glandular and EpithelialCarcinomaRadiation-Sensitizing AgentsAlbuminsInjections, IntravenousChemotherapy, AdjuvantRadiometryChemistry, PharmaceuticalAntibodies, MonoclonalAdenocarcinomaDose-Response Relationship, RadiationBiological AvailabilityPlatinum CompoundsInhibitory Concentration 50Polyethylene GlycolsAntibiotics, AntineoplasticEstramustineEtoposidePolyglutamic AcidCyclosporinsMicellesNeoplasm TransplantationNauseaNeoplasm Recurrence, LocalDisease ProgressionInfusions, ParenteralMetabolic Clearance RateAlopeciaSalvage TherapyDrug HypersensitivityDouble-Blind Method